What the survodutide schedule assumes about a person it has never met
We work the arithmetic out in full, because it is arithmetic and it is short.
Dosing
Page 6 of 31 of this archive, newest first.
Switzerland pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the trials adjudicated, and how
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The convention nobody explains before handing over the vial
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
Reading the receptor: what distinguishes survodutide from liraglutide at the molecular level
Receptor pharmacology explains more of the clinical picture than the dose does — and almost none of it appears in the material patients are given.
Holding a dose is a decision, not a failure
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
The shortage years, and what they taught about interruption
Why the reason for stopping changes what happens afterwards.
Coming off: what the pharmacology permits
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
The brainstem does most of the work
A tour of the tissues where the receptor is expressed, and what happens in each.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Beta-arrestin, cAMP, and the part of dulaglutide’s mechanism nobody quotes
The receptor is expressed in more tissues than the popular account allows, and that is the whole story.
Poland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
An error taxonomy for a market without a pharmacist
The recurring errors in this market are not exotic. They are a small set of arithmetic and reading failures, each capable of moving a dose by a factor of two or ten.
The interventions with trial support, and the much longer list without
Constipation is the most tractable of the effects and the most consistently under-managed.
The lowest effective dose is a real concept with almost no data behind it
What the labels permit, what clinicians do, and the size of the gap between them.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
When to stop escalating and when to stop entirely
We set out the questions that distinguish a symptom to manage from a dose to change.
Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
What changing your injection day does to retatrutide exposure, and what it does not
What the pharmacokinetic data supports about dose timing, missed doses and interruption.